

Poly Medicure Limited Annual Report 2015-16



innovation

safety

quality

we Care as we Cure™...



Corporate Information

Board of Directors

Chairman

Devendra Raj Mehta

Non-Executive Independent Directors

Prakash Chand Surana Yeshwant Singh Choudhary Shailendra Raj Mehta

Non-Executive Director

Jugal Kishore Baid Mukulika Baid

Managing Director

Himanshu Baid

Executive Director

Rishi Baid

Company Secretary

Avinash Chandra

Key Executives

Vishal Baid, President (Corporate Sales & Marketing)

V. K. Khera, Sr. V P (Export)
J. K. Oswal, V P (Finance) and CFO

Hemant Bhalla, V P (Sales & Marketing)

Bankers

State Bank of India Citibank N.A.

Auditors

M/s Doogar & Associates
New Delhi

Cost Auditors

M/s Jai Prakash & Co. Faridabad

Registrar and Transfer Agents

MAS Services Limited, T-34, 2nd Floor, Okhla Industrial Area, Phase-II, New Delhi-110020

Tel:+ 91(011)-26387281/82 Fax No. 011- 26387384

E-mail: mas_serv@yahoo.com Website: www.masserve.com

Registered Office

232B, 3rd Floor, Okhla Industrial Estate, Phase III

New Delhi - 110020 (India)

Tel No.: 91 11 - 26321838, 81, 89, 93

Fax No.: 91 11 - 26321839, 94

Email: investorcare@polymedicure.com

Website: www.polymedicre.com CIN: L40300DL1995PLC066923




Inside this Report:

Company	Key Performance Indicator	3
Overview	Manufacturing Facilities	
	Product Range	5
	Financial Highlights	6
	Letter to Shareholders	7
Statutory	Notice of Annual General Meeting	11
Reports	Directors' Report	20
	Management Discussion and Analysis	46
	Report on Corporate Governance	58
Financial	Independent Auditors' Report on Financial	72
Statements	Statements	12
	Balance Sheet	77
	Statement of Profit and Loss	78
	Cash Flow Statement	<i>7</i> 9
	Significant Accounting Policies	80
	Notes on Financial Statements	84
	Independent Auditors' Report on Consolidated	104
	Financial Statements	104
	Consolidated Balance Sheet	109
	Consolidated Statement of Profit and Loss	110
	Consolidated Cash Flow Statement	111
	Significant Accounting Policies on Consolidated	112
	Accounts	112
	Notes on Consolidated Accounts Financial	116
	Statements	110
	Statement of Salient features of the Financial	137
	Statements of Subsidiaries and Associate	137



Key Performance Indicators:

Revenue (₹ Crore)



EPS (₹) Adjusted with bonus




PAT (₹ Crore)




Gross Fixed Assets (₹ Crore)




EBIDTA (₹ Crore)




Dividend (in %), Adjusted with bonus



Net Worth (₹ Crore)



Market Capitalisation (₹ Crore)





Manufacturing Facilities



Unit I at Faridabad, Haryana



Unit II at Faridabad, Haryana



Unit III at Haridwar, Uttarakhand



Unit IV at SEZ Jaipur, Rajasthan



100% Subsidiary in China

Automatic Production Lines







Product Range:

Infusion Therapy

Safety I.V. Cannula

I.V. Cannula

Quick Flashback I.V. Cannula

Needle Free Systems

Three Way Stop Cocks

I.V. Infusion Sets

I.V. Flow Regulators

Extension Lines

CVP Manometer

Safety Scalp vein Sets

Vial Access Spike

Burette Set

Central Venous Access Catheters

Central Venous Catheters (Single / Double / Triple Lumen)

Anaesthesia

Oxygen Catheters

Suction Catheters

Guedel Airways

Respiratory Exerciser

Nasal Oxygen Tubes

Oxygen Masks

Aerosol Therapy masks

Fixed Concentration Masks

Endotracheal Tubes

Tracheostomy Tubes

Spinal Needles

Catheter Mount

Urology

Urine Collection Bags

Measured Volume Urine Meter

Urine Drainage Catheters

TUR Sets

Foley Balloon Catheters

Irrigation Sets

Gastroenterology

Ryle's Tubes

Levin's Tubes

Infant Feeding Tubes

Mucus Extractors

Umbilical Catheter

Feeding Bag

Blood Management & Blood Collection Systems

Blood Administration Sets

Blood Bag Systems

Blood Collection Tubes and Needles

Safety Blood Collection Sets

Quadruple Blood Bag with In-Line RBC Filter

Blood Collection Needle with flashback

Luer Adaptor

Standard Needle Holder

ESR Pipette

Surgery and Wound Drainage

Redon Drains

Thoracic Drainage Catheters

Abdominal Drainage Sets

Under Water Seal Drainage Systems

Yankauer Suction Sets

Dialysis

Fistula Needles

Safety Fistula Needles

Blood Lines

Haemodialysis Catheter

Peritoneal Dialysis Set

Peritoneal Dialysis Transfusion Set

Others

Injection Stopper

Insulin Syringes

Umbilical Cord Clamps

Sputum Collector

Dry Brush

Leur Lock Injection Site

Cannula Fixator

Universal Cap



Financial Highlights (Standalone)

					(₹ in lacs)
	2015-16	2014-15	2013-14	2012-13	2011-12
Revenue From Operations (Net)	39,447.84	37,368.83	31,233.32	25,223.79	20,891.86
Total Revenue	40,286.34	38,190.97	31,339.52	25,260.55	20,953.81
Earnings Before Depreciation, Finance	9,284.65	9,085.46	7,369.56	5,152.02	4,577.28
Cost and Tax Expenses (EBDIT)					
Depreciation and Amortisation	2,018.79	1,808.99	1,351.06	1,182.06	995.52
Exceptional Items	-	(1,957.80)	(991.46)	-	-
Net Profit	4,730.75	6,101.72	4,303.21	2,402.92	1,925.96
Dividend Payout	1323.40	1,102.84	881.33	440.50	330.38
Equity Share Capital	2205.67	2,205.67	2,203.32	1,101.25	1,101.25
Reserves and Surplus	20,177.89	16,991.29	12,226.21	10,002.73	8,188.32
Net Worth	22,383.56	19,196.96	14,429.95	11,103.98	9,289.57
Gross Fixed Assets	30,217.75	26,194.87	21,335.69	15,719.38	13,539.00
Net Fixed Assets	19,096.77	17,046.39	14,008.95	9,715.95	8,673.33
Total Assets	37,585.03	35,445.67	28,248.21	21,193.00	17,976.48
Market Capitalisation	1,25,238.06	2,22,684.65	99,656.00	49,556.00	27,928.00
Number of Employees	1594	1586	1478	1329	1210

Key Indicators

	2015-16	2014-15	2013-14	2012-13	2011-12
Earnings Per Share - (₹)*	10.72	13.83	9.77	5.45	4.37
Book Value Per Share - (₹)*	50.74	43.52	32.75	25.21	21.09
Debt : Equity Ratio	0.35:1	0.40:1	0.46:1	0.44:1	0.49:1
EBDIT/ Net Turnover %	23.54%	24.31%	23.60%	20.43%	21.91%
Net Profit Margin %	11.99%	16.33%	13.78%	9.53%	9.22%
RONW %	21.13%	31.78%	29.82%	21.64%	20.73%

^{*}Adjusted for issue of Bonus Share in FY 2013-14 in the ratio of 1:1

^{*}Adjusted for sub-division of nominal face value of one equity share of ₹ 10 each into two equity share of ₹ 5 each in FY 2014-15.



LETTER FROM THE CHAIRMAN



Dear Shareholders,

I am Delighted to present 21st Annual Report of your Company for F.Y. 2015-16.

I will begin with our vision of "Highest Quality of Healthcare to the mankind at affordable prices" keeping in eyes such vision we have started the Company in 1995. And this is more pleasant to share with you that we have succeeded to greater extent in fulfillment of such vision. We are providing our products of medical devices in more than 95 Countries and in a major portion of India on a reasonable prices without compromising in the quality.

Despite the current challenges compared to global market, some of the advantages India will continue to offer in areas like reduced cost of labor, a high level of technical expertise, and funding from governments for R&D investment to accelerate new product development has made India most favored destinations for outsourcing manufacturing services. With more and more multinational firms are looking at customizing their products to suit country specific requirements, the segment is only likely to grow in the coming years.

Your Company has demonstrated an impressive financial performance during the year 2015-16 as Company's total revenue increased from ₹ 398.47 crore to ₹ 420.52 crore during the year. Likewise, EBIDTA expanded to ₹ 94.04 crore as against ₹ 92.24 crore during the preceding year.

Corporate Governance and Ethical Management are critical aspects of modern business. Your Company not only seeks to pursue efficient management and ensure global competiveness but also fulfill the corporate social responsibility through ethical and sustainable management. Today, Our Company is contributing to the Corpus of various reputed NGO's which has been strengthening livelihood by removing hunger, malnutrition and promoting the education. To this end, the Board has adopted a number of policies to support good corporate citizenship that is important for our long-term success and creating value for our stakeholders.

Our employees contribute significantly to our business operations. Employee training and development is a shared responsibility of management and the individual employee. We are focusing on recruiting, training, employee relations or benefits, through Training and development, we ensure that employees are trained and have continuous development.

Further, your company is continuously strives for the advancement and betterment of its products. The Company is hiring talented engineers time to time and making our R&D department more stronger. Our new Research and Development center, with an investment of ₹ 12.5 crore will be operational by Q3 of fiscal 2016.

Going forward, we shall also bring in more efficiencies/automation in our business processes in order to provide greater value to our stakeholders. We are also in process of implementing SAP based ERP solution and the benefits of the same will be seen in near future. Through our new investment of approximately ₹ 60 crore in the green field project at IMT Faridabad in Haryana, which is scheduled to be commissioned in third quarter of 2017 with all statutory approvals, we will significantly broaden our existing manufacturing facilities to tap on new market opportunities in the field of Oncology, Nephrology & Respiratory care segments.

The company through its innovative manufacturing and R&D efforts will launch 8-10 new products in the coming financial year. Our international market strategy includes, Increasing the basket of products with existing customers, Organizing Training Program for Global Distributors, Participation in various conferences and exhibitions, appointment of representatives in key markets.

Poly Medicure Limited Annual Report 2015-16



The Journey is very pleasant yet, it is just the beginning phase of the Company, going forward, we shall continue to create value for our customers through innovation.

I will conclude with the resolve that we will continuously seek and strive to do good act better and do what is best for us and our stakeholders. Every success and every achievement on individual and on organizational level will be a big achievement.

D. R. Mehta New Delhi Chairman 8th August 2016



A LETER TO THE SHAREHOLDES FROM THE MANAGING DIRECTOR



Dear Shareholders,

As we enter the two decades of Poly Medicure's business I wish to thank all my colleagues, investors and stakeholders for their continuous support in growth and development of the Company.

During the last 2 decades Poly Medicure has provided the patients high quality medical devices at affordable prices and helped in saving major costs.

During the last 12 months your company has entered into several new markets and is now exporting its products to more than 95 countries. We have also made significant progress in the home market. The company's products are present in over 3000 key hospitals and has expanded its Distributor & Dealer network in every State. The Company has also added over 80 persons in Domestic Sales and Marketing team over past 12 months.

The Company believes in strong values, rich heritage, commitment to consumer satisfaction and a culture of Innovation, Safety and Quality. These remain the key pillars of our strength and foundation for future growth.

I am pleased to share with you the financial performance during financial Year 2015-16. Your Company achieved a net sales of ₹ 412.25 Crores, as against the ₹ 390.35 Crore in previous financial year. EBIDTA improved to ₹ 94.04 Crores as from ₹ 92.24 Crores in the preceding year. Your company has continues to reward its shareholders with

handsome dividends. In the year under review an interim dividend of $\stackrel{?}{\stackrel{?}{\stackrel{}}{\stackrel{}}}$ 2.50 per Share was declared and paid, further the Board has also recommended a final dividend of $\stackrel{?}{\stackrel{}{\stackrel{}}{\stackrel{}}}$ 0.50 per share for the financial year ended on 31st March, 2016.

The Company is in the process of expanding its product range in Infusion Therapy and Blood Management products. Several new products are in the development phase and will be launched in next 6 to 12 months. Through its strong R & D base the Company is focusing on new product categories like Nephrology, Oncology and Respiratory care products. Products under these new categories will be available in next 12 to 24 months.

In view of the government's emphasis on "Make in India" & mushrooming of hospitals of all sizes and categories in the Country, and a general sluggishness in the global healthcare market, our plans to focus more on the domestic markets in the immediate future has started to yield good results.

We have been recognized as the highest exporter of plastic medical disposables/ surgical devices from 2011-12 to 2014-15 (continuously for 4 years) by the Plastics Export Promotion Council, sponsored by Department of Commerce, Government of India, and have also received the 'Gold Award' for 2014-15 in recognition of our commendable contribution in Medical Devices/ Surgical/ Diagnostics Category from the Pharmaceuticals Export Promotion Council of India, supported by the Department of Commerce, Government of India. Approximately 65.57% of our total revenues were attributable to export of our products for fiscal 2016.

Going forward our top priorities for the next few years are as follows:

- 1. Focus on domestic market and increase reach to 5000 Hospitals in next 2 years
- 2. Increase focus on critical care products
- Accelerate introduction of new products by expanding the R & D team
- 4. Focus on Technology Up gradation and Automation
- 5. Tie up with Key Academic Institutions
- 6. Expand export business with fast tracking Registration process in Startegically important markets.